Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer

Author： Chen Xiaosong   Ye Guolin   Zhang Chenfang   Li Xinzheng   Chen Yiding   Xie Xiaohong   Zheng Hong   Cao Yali   Wu Kejin   Ni Duo   Tang Jinhai   Wei Ziguo   Shen Kunwei  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.142, Iss.3, 2013-12, pp. : 549-558

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

By Ohno S.   Chow L.   Sato N.   Masuda N.   Sasano H.   Takahashi F.   Bando H.   Iwata H.   Morimoto T.   Kamigaki S.   Nakayama T.   Nakamura S.   Kuroi K.   Aogi K.   Kashiwaba M.   Yamashita H.   Hisamatsu K.   Ito Y.   Yamamoto Y.   Ueno T.   Fakhrejahani E.   Yoshida N.   Toi M.  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 69-80

Springer Publishing Company

Access to resources Recommend Favorite

Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide

By Andersen Kenneth Geving   Jensen Maj-Britt   Kehlet Henrik   Gärtner Rune   Eckhoff Lise   Kroman Niels  

Acta Oncologica, Vol. 51, Iss. 8, 2012-11 ,pp. : 1036-1044

Informa Healthcare

Access to resources Recommend Favorite

Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer

By Abe Hajime  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 487-491

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

By Aogi Kenjiro   Saeki Toshiaki   Nakamura Seigo   Kashiwaba Masahiro   Sato Nobuaki   Masuda Norikazu   Rai Yoshiaki   Ohno Shinji   Kuroi Katsumasa   Nishimura Reiki   Miyakoda Keiko   Akiyama Futoshi   Kurosumi Masafumi   Ikeda Tadashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 598-606

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

By Pierga Jean-Yves   Delaloge Suzette   Espié Marc   Brain Etienne   Sigal-Zafrani Brigitte   Mathieu Marie-Christine   Bertheau Philippe   Guinebretière Jean   Spielmann Marc   Savignoni Alexia   Marty Michel  

Breast Cancer Research and Treatment, Vol. 122, Iss. 2, 2010-07 ,pp. : 429-437

Springer Publishing Company

Access to resources Recommend Favorite